About IGEA Pharma N.V.

IGEA Pharma focuses on health-tech and med-tech products and devices.

Health-tech products are exclusively preventative. IGEA commercializes an Alzheimer’s prevention solution (which includes ’Alz1’, an at-home lab test kit to measure non-bound copper in the blood and ‘Alz1 Tab’, a natural dietary supplement designed to reduce blood heavy metals content) and expects to launch a diabetes type II prevention solution in 2020. Non-ceruloplasmin bound copper is an expected Alzheimer’s and diabetes type II associated biomarker. Determining and regulating non-bound copper can contribute to reduce the risk of Alzheimer’s and diabetes type II.

IGEA is listed on the SIX Swiss Exchange and is headquartered in Hoofddorp, the Netherlands.